Intellia Therapeutics (NTLA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas Biliouris from BMO Capital reiterated a Buy rating on the stock and has a $50.00 price target.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight Intellia Therapeutics’ strategic positioning and potential for growth. The company is on track with its 2025 strategic plan, aiming for the launch of three in vivo gene editing therapies between 2027 and 2030. This forward-looking approach is supported by promising data from their Nex-z/NTLA-2002 programs, which show potential differentiation from competitors, particularly in the ATTR-CM and ATTR-PN indications.
Furthermore, Intellia’s financial position is robust, with a significant cash reserve expected to support operations into the first half of 2027. The removal of uncertainties around IND approval in the U.S. and the belief that ongoing CRISPR/Cas9 IP litigations will not materially affect the company also contribute to the positive outlook. These factors, combined with the potential for Intellia’s therapies to offer unique benefits in crowded treatment spaces, underpin the Buy rating.
According to TipRanks, Biliouris is an analyst with an average return of -11.6% and a 31.68% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Legend Biotech, and Beam Therapeutics.
In another report released today, Barclays also maintained a Buy rating on the stock with a $26.00 price target.